EGFR and glioblastoma: A phase I pharmacokinetic trial (NCT03603379) evaluated the tolerability and effectiveness of DOX-loaded anti-EGFR immunoliposomes for delivering drugs to relapsed GBM patients with EGFR amplification (Figure 6A).